Carboplatin-Teva 10 mg/ml Concentrate for Solution for Infusion

DRUG2 trials

Sponsors

Glaxosmithkline Research & Development Limited, Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS

Conditions

Lung CancerNon-Small Cellbreast cancer

Phase 2

A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

CompletedCTIS2023-505894-33-00

Glaxosmithkline Research & Development LimitedLung Cancer, Non-Small Cell

Start: 2020-11-25End: 2024-09-10Target: 114Updated: 2024-02-29

Optimization of De-EscalatiON strategies in early breast cancer

Not yet recruitingCTIS2026-527524-27-00

Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCSbreast cancer

Target: 1Updated: 2026-09-14